Tuesday, December 12, 2017 3:13:37 PM
BUT - you'd better hold that money (Broker may not let you spend it right away), because within like 5 days, you MUST "BUY to cover" your short position. So, you MUST BUY 10,000 shares within 5 days. If the price drops to $2.90/share when you BtC, you only spend $29,000 to cover your short - you keep the remaining $8,500 from the $37,500 you received originally. But, if the price rises and stays up, eventually you MUST BUY at the higher price. If it rose to $4.75 and held there, you'd have to spend the $37,500 and an additional $10,000 to cover your short. That would be a $1/sh loss.
The dangerous thing about shorting, is that as prices rise, some people sell to take profits and capitalize on increasing numbers of buyers, but some are more inclined to hold for further increases. This can reduce the number of shares available to buy, right when you NEED to buy - forcing you and other shorts to bid even higher for the shares you need. That is called "short squeeze" - if you want to see what it can be, look back about a year in the DRYS chart.
Recent MGTI News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:30:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 06:21:10 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/29/2023 05:15:26 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 12/22/2023 09:30:32 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/22/2023 09:30:32 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/22/2023 09:30:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 01:30:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/13/2023 04:29:30 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 05:27:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/27/2023 09:15:13 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM